Dr Richard Barker, Director General of the ABPI, said:
“Following comment in the media today about the UK environment for pharmaceuticals, we feel very strongly that the UK bioscience environment is world class and, with the changes underway in clinical research, we have the basis for on-going leadership in life sciences. We look forward to working with the government to capitalise on these assets in what is still the UK’s leading science-based industry."
Simon Jose, President of the ABPI, said:
"Creation of a Patent Box will further strengthen the UK’s position as a primary location for high-tech manufacturing, research and development. The ABPI looks forward to working with the Government on the Growth Agenda for the Life Sciences Sector.”
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064 Email: [email protected]
We represent innovative research-based biopharmaceutical companies, both large and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing 90 per cent of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
We are the Government recognised body negotiating the pricing of branded medicines on behalf of the entire industry. Working with our Research Affiliate Members, we promote the UK as a destination of choice for international life sciences investment.